The increased risk of transmission of COVID-19 infection causes the incidence of death in health workers to escalate. It requires further research on risk factors and intervention in health worker professionals, especially on immunity factors and nutritional status. Quality of diet and nutrition is very important to support the immune system when infected. Several probiotic strains have been shown to decrease the duration and incidence of diarrhea and respiratory infections, suggesting the Gut-Lung Axis pathway. Some probiotics also improve the balance of diversity in the composition of the gut microbiota and affect body weight in obese people. Probiotics have also been shown to improve vitamin D absorption. A combination of vitamin D and probiotics may be an alternative to reduce gut dysbiosis that will directly or indirectly reduce the risk and severity of viral infections including SARS-CoV-2.
Obesity is increasing in Indonesia and is the cause of various diseases, especially in the presence of Vitamin D deficiency, a state of dysbiosis, causing an increase in the possibility of infection. Professional health workers have a high risk of COVID-19 due to high daily exposure. Based on a review conducted by Daniel et al, it was found that 7.3% of health workers at Reutters University tested positive for COVID-19. Based on data from the Indonesian Doctors Association (IDI) on July 12, 2020, it was known that 61 doctors had died. In addition, based on data from the Indonesian National Nurses Association (PPNI), 39 nurses have died during the COVID-19 pandemic. Therefore efforts to prevent the occurrence of COVID-19 infection by providing a combination of vitamin D and probiotics to modulate dysbiosis that will further reduce the risk of viral infection, especially COVID-19, needs to be investigated for its potential benefits. Primary and secondary objectives 1. Primary Objective: To investigate the effect of a combination of probiotics and vitamin D supplementation in modulating intestinal dysbiosis, and vitamin D status, in people with overweight and obesity, especially among frontline health workers. * To assess the mean changes in zonulin levels (as a parameter of gut integrity to indicate the intestinal microbiota dysbiosis) * To assess the mean changes in serum vitamin D levels 2. Secondary Objectives: * To assess the relationship between nutritional status, inflammation and immunity with the risk of COVID-19 infection in health workers. * To understand the difference in the mean episodes of Covid-19 infection between treatment and placebo groups after giving probiotics and vitamin D in people with overweight and obesity, especially among frontline health workers. Study Design: This study has 2 phases Phase 1: a Cross-sectional study with 160 people Phase 2: a double-blind, randomized, placebo-controlled trial with two arms of intervention involving a total of 80 people.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
93
Combination of two supplement that given separately
Placebo with inactive ingredient
Wisma Emergency COVID-19 Hospital (RSDC)
Jakarta, DKI Jakarta, Indonesia
Department of Nutrition (FKUI-RSCM); and Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas Indonesia
Jakarta Pusat, DKI Jakarta, Indonesia
Dr.Cipto Mangunkusumo General Hospital (RSCM)
Jakarta Pusat, DKI Jakarta, Indonesia
University of Indonesia Hospital (RSUI)
Depok, West Java, Indonesia
Zonulin level
To investigate the changes of Zonulin level during intervention
Time frame: Baseline and endline (3 month)
Vitamin D level
To investigate the changes of Vitamin D level during intervention
Time frame: Baseline and endline (3 month)
Nutritional status
Measurement of nutritional status using Body Mass Index (BMI) and waist circumference
Time frame: Baseline and endline (3 month)
Gut microbiota (optional)
Measurement of gut microbiota in fecal using Next Generation Sequencing
Time frame: Baseline and endline (3 month)
Inflammation marker
Measurement of inflammation markers IL-6, IL-10 TNF-α using ELISA
Time frame: Screening
Cathelicidin level
Measurement of cathelicidin using ELISA
Time frame: Screening
SARS COV-2
Measurement of quantitative antibody
Time frame: Screening
CD4/CD8 ratio
Measurement of CD4/CD8 ratio using flowcytometry
Time frame: Screening
Covid-19 infection
Measurement of the reduction in risk of COVID-19 infection is seen from the difference in the average episodes between groups that were examined by PCR and/or Rapid antibody tests.
Time frame: Baseline and endline (3 month)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.